NDC 67457-521-00 - piperacillin and tazobactam
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 67457-521
- Requested NDC
- 67457-521-00
- Package NDCs from labels
- 67457-521-00, 67457-521-22
- Manufacturer
- Mylan Institutional LLC
- Effective date
- 2020-07-14
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| piperacillin and tazobactam - Mylan Institutional LLC | Mylan Institutional LLC | 2020-07-14 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 67457-521-00 | EA - Each | 67457-521 | f91a4816-1fc2-4f47-982c-76899d760bd0 | 1 | 2016-07-19 |
| 67457-521-22 | EA - Each | 67457-521 | c5fedce4-d5d5-46a9-8af3-4149e3d86d51 | 1 | 2016-07-19 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| PIPERACILLIN SODIUM | ACTIVE INGREDIENT | M98T69Q7HP | PIPERACILLIN AND TAZOBACTAM INJECTION, POWDER, FOR SOLUTION [MYLAN INSTITUTIONAL LLC] | 2 | |
| TAZOBACTAM SODIUM | ACTIVE INGREDIENT | UXA545ABTT | PIPERACILLIN AND TAZOBACTAM INJECTION, POWDER, FOR SOLUTION [MYLAN INSTITUTIONAL LLC] | 2 | |
| PIPERACILLIN ANHYDROUS | ACTIVE MOIETY | 9I628532GX | PIPERACILLIN AND TAZOBACTAM INJECTION, POWDER, FOR SOLUTION [MYLAN INSTITUTIONAL LLC] | 2 | |
| TAZOBACTAM | ACTIVE MOIETY | SE10G96M8W | PIPERACILLIN AND TAZOBACTAM INJECTION, POWDER, FOR SOLUTION [MYLAN INSTITUTIONAL LLC] | 2 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Zosyn | PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM | Baxter Healthcare Corporation | 8db6bd91-2106-4bfd-8cc8-38aaf1e18d17 | 2026-05-15 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| ZERBAXA | CEFTOLOZANE AND TAZOBACTAM | Merck Sharp & Dohme LLC | 70ac1d90-eff3-4f0b-9f46-5846c571b32f | 2026-05-12 | Warnings, Adverse reactions | UXA545ABTT |
| Piperacillin and Tazobactam and Sodium Chloride | PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE | B. Braun Medical Inc. | a63ca653-27d4-45fe-a744-77e0efe45220 | 2026-05-08 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM | Civica, Inc. | 19e89f8b-316b-4dd2-9724-bfe0faeba408 | 2025-12-12 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN SODIUM,TAZOBACTAM SODIUM | WG Critical Care, LLC | 2cd82553-79dc-45f0-9755-2c08df524ed5 | 2025-10-31 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| piperacillin and tazobactam | PIPERACILLIN AND TAZOBACTAM | Civica, Inc. | 7aebc0e6-89db-4ef0-b5ab-d6b3199bcfc4 | 2025-09-08 | Warnings, Adverse reactions | ANDA065458 M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Avenacy, LLC | 668a2730-e95a-4639-a506-ae95a6502ca1 | 2025-09-01 | Boxed warning, Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM | Eugia US LLC | 39e19789-de4b-4fd1-ab1c-92f59496f496 | 2025-08-19 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM | Eugia US LLC | a5d8625e-e630-4076-bc55-46ebe861c6a5 | 2025-08-08 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| piperacillin and tazobactam | PIPERACILLIN AND TAZOBACTAM | ONESOURCE SPECIALTY PHARMA LIMITED | 28258745-12e4-4f0f-b318-4a1a1bebc928 | 2025-07-21 | Warnings, Adverse reactions | ANDA065458 M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Avenacy, LLC | 9114cea1-3338-487e-87fa-cc3a409d501a | 2025-07-07 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | BluePoint Laboratories | 1aba753c-d0c2-4b35-917a-9143dd4be468 | 2025-06-20 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Apotex Corp. | 2c8f06a2-49b2-4169-94ef-182d13d248bf | 2025-05-21 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Fresenius Kabi USA, LLC | c5cddf50-e486-4ffb-9bc6-ed67ad6bc154 | 2025-04-14 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Fresenius Kabi USA, LLC | a798faf5-cd97-4e35-a700-94c372978c46 | 2025-04-14 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Fresenius Kabi USA, LLC | 6a894b94-171f-4217-81a2-0e84796b0b41 | 2025-04-11 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Fresenius Kabi USA, LLC | c8e3cc43-238d-4a23-95dc-157c85f83184 | 2025-04-10 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM | Provepharm Inc. | 68d5384d-1691-4afc-8a1a-488f8e2ef2c5 | 2025-02-26 | Boxed warning, Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| PIPERACILLIN AND TAZOBACTAM | PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM | Provepharm Inc. | bc26ffd8-1a6e-4e16-91c1-ec67c928b3bf | 2025-02-26 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Sandoz Inc | 9b682c66-61c6-4ade-baf4-9d68911a16b8 | 2024-10-30 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.